Why Is NUVATION BIO INC A A (NUVB) Stock Up Today?

Why NUVB stock is up today

Nuvation Bio Inc A A (NUVB) rose 7.93% to $6.26 in morning trading on Monday, driven by positive updated Phase 2 clinical data for its drug safusidenib and the announcement of two new studies in IDH1-mutant glioma. The company reported a confirmed objective response rate of 52% in grade 2 IDH1-mutant glioma patients, with no new safety signals identified. These developments have reinforced the drug’s competitive profile and led to expanded clinical trials.

What Happened

Nuvation Bio announced impressive long-term efficacy and safety data for safusidenib in grade 2 IDH1-mutant glioma, supporting the launch of two new clinical studies. Among 27 Japanese patients, only one responder later progressed after a median follow-up of 38.8 months. The updated data reinforce the drug’s potential as a treatment for brain cancer, particularly in IDH1-mutant glioma, and have drawn attention from analysts. RBC Capital analyst Leonid Timashev cited the data as reinforcing safusidenib's competitive profile, while RBC maintained an Outperform rating with a price target of $19. Truist Securities also maintained a Buy rating and raised its price target to $13.

What The Data Shows

The stock has gained 3.8% over the last eight sessions, moving from $6.07 to $6.30. The 52-week range is $2.03 to $9.75, and the stock has a market cap of $1.9 billion. Despite a revenue increase of 1205.5% in the trailing twelve months, the company remains unprofitable with an EPS of -0.42 and a net margin of -102.1%. Recent insider transactions include three sales totaling $1.4 million, with no material insider purchases reported in the last 90 days.

What To Watch

The stock is currently being closely watched for its continued performance following the clinical data release and analyst updates. Investors may also monitor the broader market for biotech sector trends and potential follow-up developments from Nuvation Bio.